Efficacy of antigiardial drugs

Bibliography

• BROWN D, UPCROFT J, EDWARDS M, UPCROFT P: Anaerobic bacterial metabolism in the ancient eukaryote Giardia duodenalis. Int. J. Parasital (1998) 28(1):149–164.
   PubMed Web of Science ®Google Scholar
• HEALEY A, MITCHELL R, UPCROFT J, BOREHAM P, UPCROFT P: Complete nucleotide sequence of the ribosomal RNA tandem repeat unit from Giardia intestinalis. Nucleic Acids Res. (1990) 18(13):4006.
   PubMed Web of Science ®Google Scholar
• UPCROFT J, UPCROFT P: My favouritecell: Giardia. BioEssays (1998) 20:256–263.
   PubMedGoogle Scholar
• •Specifically written from the perspective of the authors' own research achievements in this field.
   Google Scholar
• UPCROFT P, CHEN N, UPCROFT J: Telomeric organization of a variable and inducible toxin gene family in the ancient eukaryote Giardia duodenalis. Genome Res. (1997) 7(1):37–46.
   PubMed Web of Science ®Google Scholar
• UPCROFT P, UPCROFT J: Organization and structure of the Giardia genome. Protist (1999) 150:17–23.
   PubMed Web of Science ®Google Scholar
• FARTHING M: Giardiasis. Gastroenteral Clin. North Am. (1996) 25(3):493–515.
   PubMed Web of Science ®Google Scholar
• UPCROFT J, UPCROFT P: Giardia: basic biology, genetics and epidemiology. In: Encyclopaedia of Environment Microbiology. Bitton G (Ed.), Wiley Publishers (2002):1469–1477.
   Google Scholar
• LUJAN H, MOWATT M, BYRD L, NASH T: Cholesterol starvation induces differentiation of the intestinal parasite Giardia lamblia. Proc. Natl Acad. Sci. USA (1996) 93(15):7628–7233.
   PubMed Web of Science ®Google Scholar
• UPCROFT P, UPCROFT J: Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbial Rev. (2001) 14(1):150–164.
   PubMed Web of Science ®Google Scholar
• OLSON M, CERI H, MORCK D: Giardia vaccination. Parasitol. Today (2000) 16(5):213–217.
   PubMedGoogle Scholar
• BURET A, SCOTT K, CHIN A: Giardiasis: pathophysiology and pathogenesis. In: Giardia:The Cosmopolitan Parasite. Olson B, Olson M, Wallis P (Eds), CAB International, New York (2002):109–125.
   Google Scholar
• •This chapter is the highlight of the book.
   Google Scholar
• THOMSON I, ANDERS R, BHATHAL P: Granulomatous hepatitis and cholangitis associated with giardiasis. Gastroenterology (1982) 83(2):480–483.
   PubMed Web of Science ®Google Scholar
• ROBERTS DM, CRAFT JC, MATHER FJ, DAVIS SH, WRIGHT JA Jr: Prevalence of giardiasis in patients with cystic fibrosis. J. Pediatr. (1988) 112(4):555–559.
   PubMed Web of Science ®Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI G: High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am. J Gastroenterol. (2003) 98(4):839–843.
   PubMed Web of Science ®Google Scholar
• SOTTO A, ALVAREZ J, GARCIA B, POMAR F, CENDAN A: Acute hepatic lesion caused by Giardia lamblia. Rev. Esp. Enfirm. Dig. (1990) 77(1):24–28.
   PubMed Web of Science ®Google Scholar
• UPCROFT J, MCDONNELL P, GALLAGHER A, CHEN N, UPCROFT P: Lethal Giardia from a wild-caught sulphur-crested cockatoo (Cacatua galerita) established in vitro chronically infects mice. Parasitology (1997) 114:407–412.
   PubMed Web of Science ®Google Scholar
• UPCROFT J, MCDONNELL P, UPCROFT P: Virulent avian Giardia duodenalis pathogenic for mice. Parasitol. Today (1998) 14:281–284.
   PubMedGoogle Scholar
• CHEN N, UPCROFT J, UPCROFT P: A Giardia duodenalis gene encoding a protein with multiple repeats of a toxin homologue. Parasitology (1995) 111(Pt 4):423–431.
   PubMedGoogle Scholar
• OLSON M, CERI H, MORCK D: Giardia immunoprophylaxis and immunotherapy. In: Giardia: The Cosmopolitan Parasite. Olson B, Olson M, Wallis P (Eds), CAB International, New York (2002):139–155.
   Google Scholar
• MOHAMMED S, FAUBERT G: Purification of a fraction of Giardia lamblia trophozoite extract associated with disaccharidase deficiencies in immune Mongolian gerbils (Meriones unguiculatus). Parasite (1995) 2(0:31–39.
   PubMedGoogle Scholar
• RAPPUOLI R, LOCHT C, POOLMAN J, ANDRE F, DOUGAN G: European Commission COST/STD Initiative. Report of the expert panel VIII. New vaccines, especially new combined vaccines. Vaccine (1996) 14(7):691–700.
   Google Scholar
• TOWNSON S, BOREHAM P, UPCROFT P, UPCROFT J: Resistance to the nitroheterocyclic drugs. Acta Trap. (1994) 56(2-3):173–194.
   PubMed Web of Science ®Google Scholar
• RAETHER W, HANEL H: Nitroheterocyclic drugs with broad spectrum activity. Parasitol. Res. (2003) 90:S19–S39.
   PubMed Web of Science ®Google Scholar
• LOPEZ NIGRO N, GADANO A, CARBALLO M: Evaluation of genetic damage induced by a nitroimidazole derivative in human lymphocytes: tinidazole (TNZ). Toxicol. In Vitro (2001) 15(3):209–213.
   PubMed Web of Science ®Google Scholar
• VOOLMANN T, BOREHAM P: Metronidazole resistant Trichomonas vaginalis in Brisbane. Med. J. Aust. (1993) 159(7):490.
   PubMed Web of Science ®Google Scholar
• BOREHAM P: Giardiasis and its control. Pharm. (1991) 234:271–274.
   Google Scholar
• PENDLAND S, PISCITELLI S, SCHRECKENBERGER P, DANZIGER L: In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp. Antimicrob. Agents Chemother. (1994) 38(9):2106–2110.
   PubMed Web of Science ®Google Scholar
• TOWNSON S, LAQUA H, UPCROFT P, BOREHAM P, UPCROFT J: Induction of metronidazole and furazolidone resistance in Giardia. Trans. R. Soc. Trap. Med. Hyg. (1992) 86(5):521–522.
   Web of Science ®Google Scholar
• UPCROFT J, UPCROFT P: Drug susceptibility testing of anaerobic protozoa. Antimicrob. Agents Chemother. (2001) 45(6):1810–1814.
   PubMed Web of Science ®Google Scholar
• •Describes an assay system designed to be used in the most basic laboratory.
   Google Scholar
• MOLLER M: Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery (1983) 93(1 Pt 2):165–171.
   Google Scholar
• EDWARDS D: Nitroimidazole drugs - action and resistance mechanisms. II. Mechanisms of resistance. J. Antimicrob. Chemother. (1993) 31:201–210.
   PubMed Web of Science ®Google Scholar
• ••Essential reading regarding mechanisms ofnitroimidazole action.
   Google Scholar
• BROWN D, UPCROFT J, DODD H, CHEN N, UPCROFT P: Alternative 2-keto acid oxidoreductase activities in Trichomonas vaginalis. Mol. Biochem. Parasitol. (1999) 98(2):203–214.
   PubMed Web of Science ®Google Scholar
• VAN DER WOUDEN E, THUS J, KUSTERS J, VAN ZWET A, KLEIBEUKER J: Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori. Scand. j Gastroenterol. (S) (2001) 234:10–14.
   PubMedGoogle Scholar
• TOWNSON S, UPCROFT J, UPCROFT P: Characterisation and purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis. Mol. Biochem. Parasitol. (1996) 79:183–193.
   PubMed Web of Science ®Google Scholar
• •Includes data showing mechanisms of metronidazole resistance.
   Google Scholar
• LIU S, BROWN D, O'DONOGHUE P, UPCROFT P, UPCROFT J: Ferredoxin involvement in metronidazole resistance of Giardia duodenalis. Mol. Biochem. Parasitol. (2000) 108:137–140.
   PubMed Web of Science ®Google Scholar
• UPCROFT J, UPCROFT P: Keto-acid oxidoreductase in the anaerobic protozoa. J Eukaryot. Microbia (1999) 46(4):447–449.
   PubMed Web of Science ®Google Scholar
• UPCROFT P: Multiple drug resistance in the pathogenic protozoa. Acta Trap. (1994) 56:195–212.
   PubMed Web of Science ®Google Scholar
• HOMEIDA M, DANESHMEND T, ALI H, KAYE C: Metronidazole metabolism following oral benzoyl metronidazole suspension in children with giardiasis. Antimicrob. Chemother. (1986) 18(2):213–219.
   Web of Science ®Google Scholar
• IYNGKARAN N, LEE I, ROBINSON M: Single dose treatment with Tiberal of Giardia lamblia infection in children. Scand. I Infect. Dis. (1978) 10(3):243–246.
   PubMed Web of Science ®Google Scholar
• LEVI G, DE AVILA C, AMATO NETO V: Efficacy of various drugs for treatment of giardiasis. A comparative study. Am. J Trap. Med. Hyg. (1977) 26(3):564–565.
   PubMed Web of Science ®Google Scholar
• KATZ N, CIMERMAN B, ZINGANO A, ZINGANO R, ROCHA R: A clinical trial using secnidazole suspension in children infected with Giardia lamblia. In: Secnidazole: a New Approach to 5-IVitroimidazole Therapy. Katz N, Willis A (Eds), Excerpta Medica, Amsterdam (1989).
   Google Scholar
• UPCROFT J, CAMPBELL R, BENAKLI K, UPCROFT P, VANELLE P: Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob. Agents Chemother. (1999) 43(1):73–76.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ FERREIRO G, CANCINO BADIAS L, LOPEZ-NIGRO M et al.: DNA single strand breaks in peripheral blood lymphocytes induced by three nitroimidazole derivatives. Taxied. Left. (2002) 132(2):109–115.
   Web of Science ®Google Scholar
• BURTIN P, TADDIO A, ARIBURNU 0, EINARSON T, KOREN G: Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol. (1995) 172(2 Pt 1):525–529.
   Google Scholar
• DIAV-CITRIN 0, SHECHTMAN S, GOTTEINER T, ARNON J, ORNOY A: Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology (2001) 63(5):186–192.
   PubMedGoogle Scholar
• UPCROFT J, UPCROFT P: Drug resistance and Giardia. Parasitol. Today (1993) 9(5):187–190.
   PubMedGoogle Scholar
• HALL A, NAHAR Q: Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans. R. Soc. Trap. Med. Hyg. (1993) 87(1):84–86.
   Web of Science ®Google Scholar
• ••The first large trial of albendazoletreatment for Giardia.
   Google Scholar
• EDLIND T, HANG T, CHAKRABORTI P: Activity of the anthelmintic benzimidazole against Giardia lamblia in vitro. J. Infect. Dis. (1990) 162:1408–1411.
   PubMed Web of Science ®Google Scholar
• GOTTSCHALL D, THEODORIDES V, WANG R: The metabolism of benzimidazole anthelmintics. Parasitol. Today (1990) 6(4):115–124.
   PubMedGoogle Scholar
• •One paper in a whole issue of Parasita Today on benzimidazoles.
   Google Scholar
• LACEY E: The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int. J Parasitol. (1988) 18(7):885–936.
   PubMed Web of Science ®Google Scholar
• CHAVEZ B, CEDILLO-RIVERA R, MARTINEZ-PALOMA A: Giardia lamblia: ultrastructural study of the in vitro effect of benzimidazoles. j Protozoal. (1992) 39 (4):510–515.
   PubMedGoogle Scholar
• ••Excellent electron microscopy, as expectedfrom this group.
   Google Scholar
• UPCROFT J, MITCHELL R, CHEN N, UPCROFT P: Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in I3-tubulin. Microb. Drug Resist. (1996) 2(3):303–308.
   PubMed Web of Science ®Google Scholar
• UPCROFT J, CAMPBELL R, UPCROFT P: Quinacrine-resistant Giardia duodenalis. Parasitology (1996) 112:309–313.
   PubMed Web of Science ®Google Scholar
• HARTMAN H, KYSER F: Giardiasis and its treatment. JAMA (1941) 116:2835–2839.
   Google Scholar
• GILLIN F, DIAMOND L: Inhibition of clonal growth of Giardia lamblia and Entamoeba histolytica by metronidazole, quinacrine, and other antimicrobial agents. J. Antimicrob. Chemother. (1981) 8(4):305–316.
   PubMed Web of Science ®Google Scholar
• NAMGUNG R, RYU J-S, KEE K, SOH C: The effect of metronidazole and quinacrine on the morphology and excystation of Giardia lamblia. Yonsei Rep. Trap. Med. (1985) 16:28644.
   Google Scholar
• GENEL F, ERERMIS S, AKSU G, OZTURK C, KUTUKCULER N: Quinacrine-induced psychiatric disturbances in a child with common variable immunodeficiency and chronic giardiasis. Hum. Polchopharmacol. (2002) 17(7):357–359.
   PubMed Web of Science ®Google Scholar
• DAVIDSON R: Treatment of giardiasis: the North American perspective. In: Human Parasitic Diseases, Giardiasis. Meyer E (Ed.), Elsevier, Amsterdam (1990):325–334.
   Google Scholar
• NASH T, OHL C, THOMAS E et al.: Treatment of patients with refractory giardiasis. Clin. Infect. Dis. (2001) 33:22–28.
   PubMed Web of Science ®Google Scholar
• ••Thorough histories of six patients includingside effects and outcomes.
   Google Scholar
• WARHURST D: Antimalarial drugs: mode of action and resistance./ Antimicrob. Chemother. (1986) 18(Suppl. B):51–59.
   Google Scholar
• WARHURST D, THOMAS S: Pharmacology of the malaria parasite - a study of dose-response relationships in chloroquine-induced autophagic vacuole formation in Plasmodium berghei. Biochem. Pharmacol. (1975) 24(22):2047–2056.
   PubMed Web of Science ®Google Scholar
• WEBSTER L: Drugs used in protozoal infections. In: Goodman and Gillman's Pharmacological Basis of Therapeutics. Gilman A, Rail T, Nies A, Taylor P (Eds), Peragrnon Press, New York (1960):978–1007.
   Google Scholar
• PHILLIPS K, HAILEY F: Furazolidone fortreatment of diarrhoeal disease. Trap. Doct. (1987) 17(2):89–91.
   PubMedGoogle Scholar
• BROWN D, UPCROFT J, UPCROFT P: A H20-producing NADH oxidase from the protozoan parasite Giardia duodenalis. Eur. Biochem. (1996) 241(1):155–161.
   PubMedGoogle Scholar
• MORENO S, MASON R, DOCAMPO R: Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. J. Biol. Chem. (1984) 259(10):6298–6305.
   PubMed Web of Science ®Google Scholar
• ORTIZ J, AYOUB A, GARGALA G, CHEGNE N, FAVENNEC L: Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment. Pharmacol. Ther. (2001) 15(9):1409–1415.
   PubMed Web of Science ®Google Scholar
• GILLES HM, HOFFMAN PS: Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. (2002) 18(3):95–97.
   PubMed Web of Science ®Google Scholar
• ADAGU I, NOLDER D, WARHURST D, ROSSIGNOL J: In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. (2002) 49:103–111.
   PubMed Web of Science ®Google Scholar
• ABBOUD P, LEMÉE V, GARGALA G et al.: Successful treatment of metronidazole-and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. (2001) 32:1792–1794.
   PubMed Web of Science ®Google Scholar
• ROMERO CABELLO R, GUERRERO L, MUNOZ GARCIA M, GEYNE CRUZ A: Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trap. Med. Hyg. (1997) 91(6):701–703.
   Web of Science ®Google Scholar
• KREUTNER A, DEL BENE V, AMSTEY M: Giardiasis in pregnancy. Am. J. Obstet. Gynecol. (1981) 140:895–901.
   PubMed Web of Science ®Google Scholar
• EDLIND T: Susceptibility of Giardia lamblia to aminoglycoside protein synthesis inhibitors: correlation with rRNA structure. Antimicrob. Agents Chemother. (1989) 33(4):484–489.
   PubMed Web of Science ®Google Scholar
• KATIYAR S, VISVESVARA G, EDLIND T: Comparisons of ribosomal RNA from arnitochondrial protozoa: implications for processing, mRNA binding and paromomycin susceptibility. Gene (1995) 152:27–33.
   PubMed Web of Science ®Google Scholar
• O'HANDLEY R: Giardia in farm animals. In: Giardia: The Cosmopolitan Parasite. Olson B, Olson M, Wallis P (Eds), CAB International, New York (2002):97–105.
   Google Scholar
• GIANGASPERO A, TRALDI G, PAOLETTI B, TRAVERSA D, BIANCIARDI P: Efficacy of pyrantel embonate, febantel and praziquantel against Giardia species in naturally infected adult dogs. Vet. Rec. (2002) 150(6):184–186. Expert Opin. Drug Saf. (2003) 2(6)
   Google Scholar
• PENGSAA K, LIMKITTIKUL K, POJJAROEN-ANANT C et al.: Single-dose therapy for giardiasis in school-age children. Southeast Asian J. Trap. Med. Public Health (2002) 33(4):711–717.
   PubMedGoogle Scholar
• SANGSTER N, GILL J: Pharmacology of anthelmintic resistance. Parasitol. Today (1999) 15(4):141–146.
   PubMedGoogle Scholar
• ISAAC-RENTON J, CORDEIRO C, SARAFIS K, SHAHRIARI H: Characterization of Giardia duodenalis isolates from a waterborne outbreak. J. Infect. Dis. (1993) 167(2):431–440.
   PubMed Web of Science ®Google Scholar
• •Best example of Giardia as a zoonosis.
   Google Scholar
• FARBEY M, REYNOLDSON J, THOMPSON R: In vitro drug susceptibility of 29 isolates of Giardia duodenalis from humans as assessed by an adhesion assay. Int. J. Parasitol. (1995) 25(5):593–599.
   PubMed Web of Science ®Google Scholar
• GARDNER TB, HILL DR: Treatment of giardiasis. Clin. Microbial. Rev. (2001) 14(1):114–128.
   PubMed Web of Science ®Google Scholar
• PONCE-MACOTELA M, NAVARRO-ALEGRIA I, MARTINEZ-GORDILLO M, ALVAREZ-CHACON R: In vitro effect against Giardia of 14 plant extracts. Rev. Invest. Clin. (1994) 46(5)343–347.
   Google Scholar
• CALZADA F, CERDA-GARCIA-ROJAS C, MECKES M et al.: Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium niveum. J Nat. Prod. (1999) 62(5):705–709.
   PubMed Web of Science ®Google Scholar
• AGARWAL A, SINGH M, GUPTA N et al.: Management of giardiasis by an immuno-modulatory herbal drug Pippali rasayana. j Ethnopharmacol. (1994) 44(3):143–146.
   PubMed Web of Science ®Google Scholar
• TRIPATHI D, GUPTA N, LAKSHMI V, SAXENA K, AGRAWAL A: Antigiardial and immunostimulatory effect of Piper longum on giardiasis due to Giardia lamblia. Phytother. Res. (1999) 13(7):561–565.
   PubMed Web of Science ®Google Scholar
• FARTHING M: Giardia comes of age: progress in epidemiology, immunology and chemotherapy. J Antimicrob. Chemother. (1992) 30(5):563–566.
   PubMed Web of Science ®Google Scholar
• FARTHING M, INGE P: Antigiardial activity of the bile salt-like antibiotic sodium fusidate. J. Antimicrob. Chemother. (1986) 17(2):165–171. TANABE M, FUJI WARA T: In vitro inhibition of Giardia lamblia and Trichomonas vaginalis growth by bithionol, dichlorophene, and hexachlorophene. Antimicrob. Agents Chemother. (1985) 27(1):65–70.
   Google Scholar
• EDLIND T: Tetracyclines as antiparasitic agents: lipophilic derivatives are highly active
   Google Scholar
• BELL C, CORY M, FAIRLEY T, HALL J, TID WELL R: Structure-activity relationships of pentamidine analogs against
   Google Scholar
• BOREHAM P, UPCROFT J: The activity of azithromycin against stocks
   Google Scholar
• YOUSSEF M, ESSA M, SADAKA H, (giardiasis and cryptosporidiosis). J Egypt. Soc. ParasitaL (1996) 26(3):543–553.
   PubMedGoogle Scholar
• NASH T, RICE W: Efficacies of zinc-finger-active drugs against
   Google Scholar
• SOUSA M, POIARES-DA-SILVA J: The cytotoxic effects of ciprofloxacin in Giardia lamblia trophozoites. Taxical. In Vitro (2001) 15(4-5):297–301.
   PubMed Web of Science ®Google Scholar
• JOHN T, FAUBERT G, KOKWARO J, MAHUNNAH R, KIMANANI E: Anti-giardial activity of gastrointestinal remedies of the Luo of east Africa. Ethnopharmacol. (1995) 46(1):17–23.
   PubMed Web of Science ®Google Scholar
• ANDREWS B, MYLVAGANAM H, YULE A: Sensitivity of Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis to bacitracin and its zinc salt in vitro. Trans. R. Soc. Trap. Med.
   Google Scholar
• ANDREWS B, PANITESCU D, JIPA G et al.: Chemotherapy for giardiasis: randomized clinical trial of bacitracin, bacitracin zinc, and a combination of
   Google Scholar
• FAUBERT G: Immune response to Giardia duodenalis. Clin. Microbial. Rev. (2000) 13(1):35–54.
   PubMed Web of Science ®Google Scholar
• ERLICH J, ANDERS R, ROBERTS-THOMSON I, SCHRADER J, MITCHELL G: An examination of differences in serum antibody specificities and hypersensitivity reactions as contributing factors to chronic infection with the intestinal protozoan parasite, Giardia muris, in mice. Aust. J Exp. Biol. Med. Sci. (1983) 61(Pt 5):599–615.
   PubMedGoogle Scholar
• UNDERDOWN B, ROBERTS-THOMSON I, ANDERS R, MITCHELL G: Giardiasis in mice: studies on the characteristics of chronic infection in C3h/He mice. J Immunol. (1981) 126(2):669–672.
   PubMed Web of Science ®Google Scholar
• WALTERSPIEL J, MORROW A, GUERRERO M, RUIZ-PALACIOS G, PICKERING L: Secretory anti-Giardia lamblia antibodies in human milk: protective effect against diarrhea. Pediatrics (1994) 93:28–31.
   PubMed Web of Science ®Google Scholar
• GILLIN F: Giardia lamblia: the role of conjugated and unconjugated bile salts in killing by human milk. Exp. Parasitol. (1987) 63:74–83.
   PubMed Web of Science ®Google Scholar
• ANDRZEJEWSKA M, YEPEZ-MULIA L, CEDILLO-RIVERA R et al.: Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyl-and 2-pentafluoroethylbenzimidazoles. Eur. J. Med. Chem. (2002) 37(12):973–978.
   PubMed Web of Science ®Google Scholar
• BHARTI N, HUSAIN K, GONZALEZ GARZA M et al.: Synthesis and in vitro antiprotozoal activity of 5-nitrothiophene-2-carboxaldehyde thiosemicarbazone derivatives. Bioarg. Med. Chem. Lett. (2002) 12(23):3478–3478.
   Google Scholar
• VALDEZ J, CEDILLO R, HERNANDEZ-CAMPOS A et al.: Synthesis and antiparasitic activity of 1H-benzimidazole derivatives. Bioarg Med. Chem. Lett. (2002) 12(16):2221–2224.
   PubMed Web of Science ®Google Scholar
• REYNOLDSON J: Therapeutics and new drug targets for giardiasis. In: Giardia: The Cosmopolitan Parasite. Olson B, Olson M, Wallis P (Eds), CAB International, New York (2002):159–175.
   Google Scholar
• SANGSTER N, BATTERHAM P, CHAPMAN H et al.: Resistance to antiparasitic drugs: the role of molecular diagnosis. Int. J. Parasitol. (2002) 32(5):637–653.
   PubMed Web of Science ®Google Scholar
• CHEN N, UPCROFT J, UPCROFT P: Physical map of a 2 Mb chromosome of the intestinal protozoan parasite Giardia duodenalis. Chromosome Res. (1994) 2(4):307–313.
   PubMed Web of Science ®Google Scholar
• •First map of a Giardia chromosome.
   Google Scholar
• SANGSTER N: Managing parasiticide resistance. Vet. Parasitol (2001) 98:89–109.
   PubMed Web of Science ®Google Scholar
• BOREHAM P, PHILLIPS R, SHEPHERD R: The sensitivity of Giardia intestinalis to drugs in vitro. Antimicrob. Chemother. (1984) 14:449–461.
   Web of Science ®Google Scholar
• BOREHAM P, PHILLIPS R, SHEPHERD R: Heterogeneity in the responses of clones of Giardia intestinalis to anti-giardial drugs. Trans. R. Soc. Trap. Med. Hyg. (1987) 81:406–407.
   Web of Science ®Google Scholar
• MCINTYRE P, BOREHAM P, PHILLIPS R, SHEPHERD R: Chemotherapy in giardiasis: clinical responses and in vitro drug sensitivity of human isolates in axenic culture. J. Pediatr. (1986) 108(6): 1005–1010.
   PubMed Web of Science ®Google Scholar
• •The original report of clinical drug resistance in Giardia.
   Google Scholar
• UPCROFT J, BOREHAM P, CAMPBELL R, SHEPHERD R, UPCROFT P: Biological and genetic analysis of a longitudinal collection of Giardia samples derived from humans. Acta Trop. (1995) 60(1):35–46.
   PubMed Web of Science ®Google Scholar
• LEMÉE V, ZAHARIA I, NEVEZ G et al.: Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J. Antimicrob. Chemother. (2000) 46(5):819–821.
   PubMed Web of Science ®Google Scholar
• ••Clear demonstration of clinical metronidazoleand albendazole resistance in Giardia.
   Google Scholar
• KOORTBEEK L, LIMPER L, TOLBOOM J, NABER A: Giardia lamblia resistance against nitroimidazole; albendazole therapy. In: Giardia —from Molecules to Disease. Thompson R, Reynoldson J, Lyrnbery A (Eds), CAB International, Wallingford (1994):374.
   Google Scholar
• BUTCHER P, CEVALLOS A, CARNABY S et al.: Phenotypic and genotypic variation in Giardia lamblia isolates during chronic infection. Gut (1994) 35(1):51–54.
   PubMed Web of Science ®Google Scholar
• JOKIPII L, JOKIPII A: Single-dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects, and drug absorption and elimination. J. Infect. Dis. (1979) 140(6):984–988.
   PubMed Web of Science ®Google Scholar
• LO LINE MEI C, SANKALE M, PENE P: Les giardiases rebelles. Médecine d'Afrique Noire (1987) 34(12):1063–1068.
   Google Scholar
• ROWEDDER A, MEIDER R, WEGMANN W, GYR K Combined oral and endoscopic mepacrine therapy in therapy-resistant symptomatic giardiasis. Schweiz. Med. Wochenschr. (1991) 121(38):1383–1386.
   PubMedGoogle Scholar